Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Cements Lead In Immunotherapy

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approval for Opdivo and Yervoy in combination and Opdivo as monotherapy for the treatment of all metastatic melanoma patients, regardless of BRAF mutation status, puts Bristol on equal footing with Merck in the indication, and positions it to take on the BRAF inhibitors.

You may also be interested in...



Melanoma Approvals Break New Ground In Immunotherapy

First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.

Oncologists Audition Yervoy And Zelboraf For First-line Roles, With New Combos In Near Sight

Cooperative group plans trial testing Yervoy vs. Zelboraf in first-line metastatic melanoma to help settle the issue of which therapy should come first in BRAF-mutation positive patients. New therapies on the way promise to further complicate decision-making.

J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business

The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.

Topics

Related Companies

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel